We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ceftizoxime plus ticarcillin: double beta-lactam therapy for infections in cancer patients.
- Authors
Rolston, K V; Jones, P G; Fainstein, V; Elting, L; Bodey, G P
- Abstract
Eighty-one febrile episodes in cancer patients with adequate neutrophil counts (greater than 1000/microliter) were treated with a double beta-lactam combination of ceftizoxime plus ticarcillin. Fifty-four episodes were microbiologically documented and 27 were clinically documented. The overall response rate was 75% (61 of 81). The response rate in 38 episodes where a single organism was identified was 71%. Polymicrobial infections were associated with a high response rate of 87%. Responses occurred in six of eight Gram-positive and 21 of 30 Gram-negative infections. Pneumonia was the most frequent infection and was associated with a response of 61%. Septicaemia and urinary tract infections also occurred commonly and had response rates of 76% and 89% respectively. All but one organism were susceptible to at least one of the antibiotics. No resistant organisms emerged during therapy. Side-effects included rash (1), phlebitis (3), and coagulation abnormalities without bleeding (3). Four patients developed superinfections (three bacterial, one fungal). The double beta-lactam combination of ceftizoxime plus ticarcillin was safe and effective therapy for infections in non-neutropenic cancer patients.
- Subjects
BACTERIAL disease complications; PENICILLIN; BACTERIAL diseases; CEFOTAXIME; COMBINATION drug therapy; COMPARATIVE studies; FEVER; GRAM-negative bacteria; GRAM-positive bacteria; RESEARCH methodology; MEDICAL cooperation; PNEUMONIA; RESEARCH; SEPSIS; TICARCILLIN; TUMORS; EVALUATION research; CEFTAZIDIME; DISEASE complications; THERAPEUTICS
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 1987, Vol 19, Issue 3, p367
- ISSN
0305-7453
- Publication type
journal article